Jessica G. Y. Luc

Jessica G. Y. Luc

Auto-generated profile, based on publicly available information

Jessica G. Y. Luc

Division of Cardiovascular Surgery, Department of Surgery, University of British Columbia, Vancouver, BC, Canada

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in The American Journal of Surgery
Verified
Journal Article
Closed access
JLJessica G.Y. Luc
Jessica G.Y. Luc
NSNikki L. Stamp
Nikki L. Stamp
MAMara Antonoff
Mara Antonoff

1 September 2016 in Journal of Thoracic Disease
Verified
Journal Article
Closed access
PDF file
JXJoshua Xu
Joshua Xu
JLJessica G. Y. Luc
Jessica G. Y. Luc
KPKevin Phan
Kevin Phan
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia in modern clinical practice, with an estimated prevalence of 1.5–2%. The prevalence of AF is expected to double in the next decades, progressing with age and increasingly becoming a global medical challenge. The first-line treatment for AF is often medical treatment with either rate control or anti-arrhythmic agents for rhythm control, in addition to anti-coagulants such as warfarin for stroke prevention in patient at risk. Catheter ablation has emerged as an alternative for AF treatment, which involves myocardial tissue lesions to disrupt the underlying triggers and substrates for AF. Surgical approaches have also been developed for treatment of AF, particularly for patients requiring concomitant cardiac surgery or those refractory to medical and catheter ablation treatments. Since the introduction of the Cox-Maze III, this procedure has evolved into several modern variations, including the use of alternative energy sources (Cox-Maze IV) such as radiofrequency, cryo-energy and microwave, as well as minimally invasive thoracoscopic epicardial approaches. Another recently introduced technique is the hybrid ablation approach, where in a single setting both epicardial thoracoscopic ablation lesions and endocardial catheter ablation lesions are performed by the cardiothoracic surgeon and cardiologist. There remains controversy surrounding the optimal approach for AF ablation, energy sources, and lesion sets employed. The goal of this article is review the history, classifications, pathophysiology and current treatment options for AF.

1 January 2018 in Seminars in Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
PDF file
JLJessica G.Y. Luc
Jessica G.Y. Luc
NSNikki L. Stamp
Nikki L. Stamp
MAMara Antonoff
Mara Antonoff

1 December 2018 in Annals of Emergency Medicine
Verified
Journal Article
Closed access
BTBrent Thoma
Brent Thoma
TCTeresa M. Chan
Teresa M. Chan
PKPuneet Kapur
Puneet Kapur
DSDerek Sifford
Derek Sifford
MSMarshall Siemens
Marshall Siemens
AZAlexander Zozula
Alexander Zozula

1 February 2020 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
JLJessica G.Y. Luc
Jessica G.Y. Luc
MAMichael A. Archer
Michael A. Archer
RARakesh C. Arora
Rakesh C. Arora
EBEdward M. Bender
Edward M. Bender
ABArie Blitz
Arie Blitz
MAMara Antonoff
Mara Antonoff

1 January 2019 in Annals of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
JCJae Hwan Choi
Jae Hwan Choi
JLJessica G. Y. Luc
Jessica G. Y. Luc
MWMatthew P. Weber
Matthew P. Weber
HRHaritha G. Reddy
Haritha G. Reddy
EMElizabeth J. Maynes
Elizabeth J. Maynes
VTVakhtang Tchantchaleishvili
Vakhtang Tchantchaleishvili
Background: Heparin-induced thrombocytopenia (HIT) is a severe antibody-mediated reaction leading to transient prothrombosis. However, its incidence in patients on extracorporeal life support (ECLS) is not well described. The aim of this systematic review was to report the incidence of HIT in patients on ECLS, as well as compare the characteristics and outcomes of HIT in patients undergoing veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and veno-venous ECMO (VV-ECMO). Methods: An electronic search was performed to identify all studies in the English literature examining outcomes of patients with HIT on ECLS. All identified articles were systematically assessed using specific inclusion and exclusion criteria. Random effects meta-analysis as well as univariate analysis was performed. Results: Of 309 patients from six retrospective studies undergoing ECLS, 83% were suspected, and 17% were confirmed to have HIT. Due to the sparsity of relevant retrospective data regarding patients with confirmed HIT on ECLS, patient-based data was subsequently collected on 28 patients from case reports and case series. Out of these 28 patients, 53.6% and 46.4% of them underwent VA-ECMO and VV-ECMO, respectively. Patients on VA-ECMO had a lower median platelet count nadir (VA-ECMO: 26.0 vs. VV-ECMO: 45.0 per µL, P=0.012) and were more likely to experience arterial thromboembolism (VA-ECMO: 53.3% vs. VV-ECMO: 0.0%, P=0.007), though there was a trend towards decreased likelihood of experiencing ECLS circuit oxygenator thromboembolism (VA-ECMO: 0.0% vs. VV-ECMO: 30.8%, P=0.075) and thromboembolism necessitating ECLS device or circuit exchange (VA-ECMO: 13.3% vs. VV-ECMO 53.8%, P=0.060). Kaplan-Meier survival plots including time from ECLS initiation reveal no significant differences in survival in patients supported on VA-ECMO as compared to VV-ECMO (P=0.300). Conclusions: Patients who develop HIT on VA-ECMO are more likely to experience more severe thrombocytopenia and arterial thromboembolism than those on VV-ECMO. Further research in this area and development of standardized protocols for the monitoring, diagnosis and management of HIT in patients on ECLS support are warranted.